SCHEMBL2808353

SCHEMBL2808353

ON=Cc1cc(SCC(F)(F)F)c2ccc3cccnc3c2n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 13/20 0.37
ALDH1A1 P00352 9/20 0.35
HPGD P15428 6/20 0.35
HSD17B10 Q99714 4/20 0.35
MAPT P10636 6/20 0.35
HTT P42858 3/20 0.35
CCR1 P32246 2/20 0.35
CCR5 P51681 2/20 0.35
CCR8 P51685 2/20 0.35
TP53 P04637 2/20 0.35
HSP90AA1 P07900 2/20 0.35
TSHR P16473 2/20 0.35
GMNN O75496 1/20 0.35
LMNA P02545 1/20 0.35
MMP2 P08253 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
MMP9 P14780 1/20 0.35
ALOX15 P16050 1/20 0.35
NFKB1 P19838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2808351 1.00 KDM4E (0.37) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL3648305 0.90 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL3648306 0.90 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL2809962 0.83 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL2809964 0.83 KDM4E (0.38) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL13127510 0.83 KDM4E (0.55) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL2805551 0.82 KDM4E (0.42) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL2805553 0.82 KDM4E (0.42) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL2805054 0.81 HSP90AA1 (0.37) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL2805058 0.81 HSP90AA1 (0.37) KDM4EALDH1A1HPGDHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140011835-A1 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES NOSCIRA, S.A. (ES) 2014-01-09 US claimed
US-20140011835-A1 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES NOSCIRA, S.A. (ES) 2014-01-09 US disclosed
US-8592446-B2 [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases NOSCIRA, S.A. (ES) 2013-11-26 US disclosed
US-20100240692-A1 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES NOSCIRA, S.A. (ES) 2010-09-23 US disclosed
EP-2170464-A2 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES NOSCIRA, S.A. (ES) 2010-04-07 EP disclosed
WO-2008152068-A2 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES NOSCIRA, S.A. (ES) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140011835-A1 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES HTT, PARK7, ATXN10 KDM4E 1412/4885ALDH1A1 319/4885HPGD 483/4885
US-20100240692-A1 [1,10]-PHENANTHROLINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE OR HAEMATOLOGICAL DISEASES HTT, ATXN10, PSEN1 KDM4E 1922/4885ALDH1A1 1502/4885HPGD 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.